Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT04526977Unknown

Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).

Role: lead

NCT04402827Completed

Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.

Role: lead

NCT04403061Completed

Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome

Role: lead

NCT02614027Completed

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

Role: lead

NCT02491242Completed

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

Role: lead

NCT03348449Completed

Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)

Role: lead

NCT02209740Completed

Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies

Role: lead

NCT02116751Completed

Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients

Role: lead

NCT01060618Phase 2Completed

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term

Role: lead

All 9 trials loaded